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A B S T R A C T
Cystoisosporosis is a leading diarrheal disease in suckling piglets. With the confirmation of resistance against the
only available drug toltrazuril, there is a substantial need for novel therapeutics to combat the infection and its
negative effects on animal health. In closely related apicomplexan species, bumped kinase inhibitors (BKIs)
targeting calcium-dependent protein kinase 1 (CDPK1) were shown to be effective in inhibiting host-cell inva-
sion and parasite growth. Therefore, the gene coding for Cystoisospora suis CDPK1 (CsCDPK1) was identified and
cloned to investigate activity and thermal stabilization of the recombinant CsCDPK1 enzyme by BKI 1369. In this
comprehensive study, the efficacy, safety and pharmacokinetics of BKI 1369 in piglets experimentally infected
with Cystoisospora suis (toltrazuril-sensitive, Wien-I and toltrazuril-resistant, Holland-I strains) were determined
in vivo and in vitro using an established animal infection model and cell culture, respectively. BKI 1369 inhibited
merozoite proliferation in intestinal porcine epithelial cells-1 (IPEC-1) by at least 50% at a concentration of
40 nM, and proliferation was almost completely inhibited (> 95%) at 200 nM. Nonetheless, exposure of infected
cultures to 200 nM BKI 1369 for five days did not induce structural alterations in surviving merozoites as
confirmed by transmission electron microscopy. Five-day treatment with BKI 1369 (10mg/kg BW twice a day)
effectively suppressed oocyst excretion and diarrhea and improved body weight gains in treated piglets without
obvious side effects for both toltrazuril-sensitive, Wien-I and resistant, Holland-I C. suis strains. The plasma
concentration of BKI 1369 in piglets increased to 11.7 μM during treatment, suggesting constant drug accu-
mulation and exposure of parasites to the drug. Therefore, oral applications of BKI 1369 could potentially be a
therapeutic alternative against porcine cystoisosporosis. For use in pigs, future studies on BKI 1369 should be
directed towards ease of drug handling and minimizing treatment frequencies.
1. Introduction
Calcium-dependent protein kinases (CDPKs) are promising targets
for the development of anti-apicomplexan drugs (Hui et al., 2015;
Kugelstadt et al., 2011; Ojo et al., 2013). Apicomplexan CDPKs, be-
longing to a superfamily of serine-threonine kinases, are among the
most abundant classes of calcium sensors and are crucial for multiple
physiological functions such as gliding, cell invasion, egress and
replication (Kugelstadt et al., 2011; Ojo et al., 2012). Most importantly,
these CDPKs are absent in mammalian hosts, rendering them excellent
parasite-specific drug targets (Billker et al., 2009; Larson et al., 2012;
Ojo et al., 2010). CDPKs in apicomplexan parasites can be effectively
targeted by bumped kinase inhibitors (BKIs), a class of synthetic com-
petitive inhibitors of ATP-binding. BKI selectivity is based on a small
‘gatekeeper’ residue present in apicomplexan CDPK1 (Keyloun et al.,
2014). This allows for BKIs with large aromatic moieties displayed from
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the C-3 position of the pyrazolopyrimidine scaffold to selectively target
the apicomplexan enzyme and not mammalian or other parasite ki-
nases.
A wide range of BKIs have already been evaluated for efficacy
against coccidian parasites such as Toxoplasma gondii (Doggett et al.,
2014; Johnson et al., 2012; Winzer et al., 2015), Neospora caninum (Ojo
et al., 2014; Sánchez-Sánchez et al., 2018), Besnoitia besnoiti (Jiménez-
Meléndez et al., 2017), Sarcocystis neurona (Ojo et al., 2016) and
Cryptosporidium parvum (Hulverson et al., 2017; Schaefer et al., 2016).
No consistent side effects of BKIs have been observed in these in vivo
trials. Cystoisospora suis is a close relative of T. gondii and N. caninum
within the family Sarcocystidae (Ogedengbe et al., 2015; Samarasinghe
et al., 2008). Therefore, existence of the ortholog of CDPK1 in C. suis
and consequently efficacy of BKIs, originally developed for inhibition of
TgCDPK1, was expected.
C. suis (syn. Isospora suis) is one of the leading causes of diarrheal
disease in suckling piglets. The disease is usually non-fatal but of high
morbidity in affected litters (Lindsay et al., 1985; Roepstorff et al.,
1998; Sayd and Kawazoe, 1998). Cystoisosporosis is characterized by
watery-to-pasty non-hemorrhagic diarrhea, impaired weight gain and
reduced and uneven weaning weights in piglets, and consequently
imposes significant economic losses on the pig farming industry (Mundt
et al., 2005, 2007; Shrestha et al., 2015). The triazinone toltrazuril is
the only commercially marketed compound available for effective
treatment of cystoisosporosis. Due to the enforcement of strict regula-
tions on the use of anticoccidials in many countries and, most im-
portantly, the emergence of resistance against toltrazuril in C. suis
(Shrestha et al., 2017), the search for alternative effective therapeutic
and control strategies against cystoisosporosis is a priority.
BKIs targeting apicomplexan CDPK1 have been shown to inhibit
parasite infection in vitro and/or in representative animal models. In the
present study, BKI 1369 successfully ameliorated cystoisosporosis in its
natural host, the pig, employing experimental infections with two dif-
ferent strains of C. suis with varying susceptibility to toltrazuril. The in
vivo results were further supported by in vitro demonstration of efficacy
against C. suis merozoites in IPEC-1 cell cultures and genetic and
functional studies on the putative target enzyme, CsCDPK1. Repeated
oral applications of BKI 1369 showed marked systemic exposure after
treatment, significantly reduced oocyst excretion and diarrhea, and
improved body weight gains in treated piglets. The results of the animal
experimental and in vitro studies thus validate BKI 1369 as a potential
therapeutic candidate against porcine cystoisosporosis, and they also
have possible implications for efficacy studies of BKI 1369 against cy-
stosiospororsis in other mammalian hosts.
2. Materials and methods
2.1. Compounds used
BKIs 1369 and 1318 (metabolite 1) were synthesized to> 95%
purity as assessed by high performance liquid chromatography (HPLC)
as previously described (Johnson et al., 2012; Vidadala et al., 2016).
BKI 1369 for the animal studies was synthesized by VAS Bio, Cherla-
pally, Hyderabad, India to> 98% purity by HPLC and nuclear magnetic
resonance (NMR) with<0.5% of any single impurity by HPLC and to
less than 10 parts per million of heavy metal contamination. BKI 1817
(metabolite 2) (Hulverson et al., 2017; Lee et al., 2018) was synthesized
as follows: BKI 1369 was added to concentrated hydrochloric acid and
stirred for 8 h at 60 °C. The reaction mixture was first neutralized and
then basified (pH=8–9) using aqueous sodium bicarbonate followed
by extraction with ethyl acetate (3×10ml). The organic layers were
combined, concentrated by rotary evaporator and purified by reverse
phase-HPLC in acetonitrile: water to yield BKI 1817 (metabolite 2).
Synthesis of BKI 1817: 1H NMR (500MHz, CD3OD) δ 8.47 (s, 1H), 8.07
(d, J=8.9 Hz, 1H), 8.02 (s, 1H), 7.90 (d, J=8.3 Hz, 1H), 7.56 (d,
J=8.0 Hz, 1H), 6.71 (d, J=9.4 Hz, 1H), 4.50 (d, J=6.2 Hz, 2H), 3.55
(m), 3.34 (s, 1H), 2.49 (m, 2H), 3.36 (s, 3H), 2.41 (s, 1H), 2.28 (m, 2H),
1.69 (m, 2H); MS (ESI) 390.3m/z [MH+], C21H24N7O requires 389.5;
HPLC purity> 95%.
2.2. Molecular cloning, protein expression, purification and enzyme activity
of CsCDPK1
Amino acid sequences of relevant BKI-binding CDPK1 proteins from
closely related apicomplexan species T. gondii [accession no.
TGME49_301440], N. caninum [NCLIV_011980], S. neurona
[SRCN_3314], B. besnoiti [KY991370] and Hammondia hammondi
[HHA_301440] were obtained from ToxoDB (http://toxodb.org) and
NCBI (https://www.ncbi.nlm.nih.gov/) and compared with amino acid
sequences of all protein kinases predicted in the C. suis genome
(GenBank® accession number: PRJNA341953) using BLASTP (https://
blast.ncbi.nlm.nih.gov/Blast.cgi) to identify the C. suis ortholog
(CsCDPK1). The sequences were then aligned and analyzed using
Clustal Omega (Sievers et al., 2011).
The complete reading frame of CsCDPK1 was amplified by PCR and
cloned into the ligation independent cloning (LIC) site of protein ex-
pression vector AVA0421 (Ojo et al., 2011). Expression vector plasmid
DNA was purified using the ZymoPURE Plasmid Kits (Zymo Research,
Irvine, CA). A comparative analysis of the nucleotide sequence of the
DNA insert to GenBank® entries was used to confirm it as the putative
CsCDPK1 gene. Recombinant expression of CsCDPK1 was performed in
Rosetta Oxford Escherichia coli (Invitrogen, Carlsbad, CA, USA) at 20 °C
using Studier auto-induction protocols (Studier, 2005). Soluble re-
combinant CsCDPK1 enzyme was purified as described previously (Ojo
et al., 2011). Recombinant enzyme activity and inhibition of CsCDPK1
kinase phosphorylation properties by small molecule inhibitors were
measured in a non-radioactive Kinase-Glo® (Promega, Madison, WI,
USA) luciferase assay, where readout in an EnVision Multilabel Plate
Reader (PerkinElmer, Waltham, MA) was based on changes in ATP
concentration in the presence of the peptide substrate. PLKtide (Sig-
nalchem Richmond, BC, Canada) with peptide sequence CKKLGEDQ-
AEEISDDLLED-SLSDEDE was used as the receptor of the phosphate
group donated by ATP in the CsCDPK1 catalyzed phosphorylation re-
action. The activity assay reaction buffer contained 20mM 4-(2-hy-
droxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 0.1%
bovine serum albumin (BSA) (w/v), 10mM MgCl2, 1 mM ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N'-tetraacetic acid (EGTA), with
or without 2mM CaCl2. The reaction mixture included 6 nM CsCDPK1
and 68 μM PLKtide in 96-well plates with dilutions from 2 μM to
0.001 μM. The reactions were initiated by the addition of 1 μM ATP and
incubated for 90min at 30 °C and 90 rpm. Finally, the concentration of
compound resulting in a 50% reduction in the enzyme activity was
determined.
2.3. Thermal stability assay
Thermal stabilization of recombinant CsCDPK1 in the presence or
absence of inhibitors was determined in a 96-well format as previously
described (Crowther et al., 2009; Ojo et al., 2016). Each 20 μL final
assay volume contained a reaction mixture of 10 μM CsCDPK1 enzyme,
20 μM of each inhibitor, 2.5% SYPRO Orange dye (Invitrogen, Carlsbad,
CA) and 5% dimethyl sulfoxide (DMSO) in the presence or absence of
calcium. The reactions were performed in a buffered solution con-
taining 25mM HEPES (pH 7.25), 500mM NaCl, 5% glycerol, 1 mM
dithiothreitol and 0.025% sodium azide with or without 250 μM EGTA
as a calcium ion chelator. An internal control comprising of CsCDPK1
and 5% DMSO was included in each assay plate. An additional control
using previously characterized recombinant TgCDPK1 enzyme was also
included. The assay was performed in a StepOnePlus™ Real-Time PCR
system (Applied Biosystems). All assays were performed independently
at least two times (Ojo et al., 2016).
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2.4. In vitro culture of intestinal porcine epithelial cells and viability assays
Intestinal porcine epithelial cells-1 (IPEC-1; DSMZ, ACC 705; www.
dsmz.de) were maintained in culture medium at 37 °C and 5% CO2
(DMEM/HAM12 supplemented with 5% fetal calf serum and penicillin/
streptomycin; Gibco via Thermofisher, Vienna, Austria) as described
earlier (Worliczek et al., 2013). BKI 1369 was stored as a 20mM stock
solution in 100% DMSO at −20 °C. Cell viability in the presence of
DMSO and BKI 1369 was determined by a colorimetric cell proliferation
WST-1 assay (Roche Diagnostics GmbH, Mannheim, Germany) ac-
cording to the manufacturer's protocol. IPEC-1 cells in 48-well plates
(4× 104 cells/well) were incubated one day after seeding with dif-
ferent concentrations of BKI 1369 (1000 nM, 200 nM, 100 nM, 50 nM
and 25 nM diluted in culture medium and 0.005% or 0.001% of DMSO)
in quadruplicate and grown for 4 days at 37 °C with 5% CO2 in a hu-
midified incubator. After cultivation, 10 μl of WST-1 reagent was added
to each well and incubated for 3 h at 37 °C. Absorbance was measured
at 409 nm (reference wavelength 620 nm) using an ELISA plate reader
(Filter-Max F5, Molecular Devices, Sunnyvale, CA, USA). Cell viability
was compared against DMSO-only and medium-only controls.
2.5. In vitro efficacy testing
Confluent IPEC-1 cells (4× 104 cells/well) grown in 48 well plates
were infected with excysted sporozoites of C. suis (Wien-I) as described
earlier (Worliczek et al., 2013) one day after cell seeding in a ratio of
80:1. Infected cells were incubated in the presence of BKI 1369 (200,
100, 50, 25, and 12.5 nM) in culture medium continuously for 5 days
(0–4 days post infection (dpi)) to calculate the 50% and 95% inhibitory
concentrations (IC50 and IC95). After treatment for 5 days (0–4 dpi),
medium containing BKI 1369 was replaced with normal culture
medium and the culture was maintained further until 9 dpi. To evaluate
growth of the parasite, supernatants were collected and free merozoites
were counted in pooled samples at 9 dpi from quadruplicate wells in C-
Chip disposable hemocytometers (NanoEnTek/Roth Lactan, Graz,
Austria). All assays included medium-only and DMSO-only controls in
quadruplicate.
2.6. Transmission electron microscopy
Confluent IPEC-1 cells (2.5× 105 cells/well) grown in 6-well cul-
ture plates (VWR, Vienna, Austria) were infected with 5× 103 C. suis
sporozoites. The next day, cells were incubated with predetermined
IC50 (40 nM) or IC95 (200 nM) concentrations of BKI 1369 (see above
section on efficacy testing) at 40 °C for five days. Infected cells in-
cubated with 0.001% DMSO served as controls. After 24 h, 72 h, 96 h
and 120 h of incubation, medium supernatant was removed, the
monolayers were washed twice with phosphate buffer saline (PBS) and
fixed with 5% glutaraldehyde (Merck, Darmstadt, Germany) in 0.1M
sodium phosphate buffer (pH 7.2) for 10min at 4 °C. Cells were care-
fully collected using a rubber scraper (TPP, Switzerland) and subjected
to centrifugation at room temperature for 5min at 390×g. The super-
natant was removed and cells were postfixed with 1% osmium tetroxide
(Merck) for 1 h at 4 °C. After dehydration in an alcohol series and
propylene oxide (Merck), the cells were embedded in glycidyl ether 100
(Serva, Heidelberg, Germany). The ultra-thin sections were cut on a
Leica Ultramicrotome (Leica Ultracut S, Vienna, Austria), stained with
uranyl acetate (Sigma-Aldrich, Vienna, Austria) and lead citrate and
examined in a Zeiss TEM 900 electron microscope (Carl Zeiss,
Oberkochen, Germany) operated at 50 kV.
2.7. Study animals and husbandry
A total of 35 conventionally raised piglets from four crossbred sows
(Landrace x Large White) were randomly allocated to four treatment
groups (Table 1). Pregnant sows were moved to the animal husbandry
facility of the Institute of Parasitology, University of Veterinary Medi-
cine Vienna, Austria, two weeks before farrowing to acclimatize to the
housing conditions. Sows were housed on straw in individual farrowing
crates and fed once daily with a commercial feed free of coccidiostat.
The piglets received milk from the sow followed by starter feed from the
second week of life. Fresh drinking water was provided ad libitum to the
sows and piglets. Only clinically healthy piglets with a body weight
≥900 g on study day 1 (SD 1) were included in the study. The first day
after the birth of piglets was considered SD 1. The clinical study lasted
for 29 days (SD 29) and followed a blinded and randomized experi-
mental block design with the individual piglet as an experimental unit.
All the procedures involving animals were approved by the Animal
Ethics Committee of the University of Veterinary Medicine Vienna and
the national authority according to § 26ff of Animal Experiments Act,
Tierversuchsgesetz 2012-TVG 2012 (license number: BMWF-68.205/
0034-WF/V/3b/2016; Austrian Federal Ministry of Science, Health and
Economy).
2.8. C. suis oocysts, infection and BKI 1369 treatment
A toltrazuril-sensitive laboratory strain of C. suis, Wien-I (Joachim
and Mundt, 2011) and a toltrazuril-resistant field isolate of C. suis,
Holland-I (Shrestha et al., 2017), were maintained and passaged reg-
ularly in suckling piglets every 3–6 months for the production of in-
fectious oocysts at the Institute of Parasitology, University of Veterinary
Medicine Vienna, Austria. To avoid unintended mixing of the two
strains, all procedures (strain maintenance and experimental infections)
were carried out in separated trials with complete cleaning and disin-
fection of the farrowing units between trials. Oocysts of C. suis were
isolated from fecal samples and purified as described earlier (Worliczek
et al., 2013). For sporulation, purified oocysts in 2% aqueous potassium
dichromate solution were poured into petri dishes, aerated twice daily
and incubated at room temperature for 2–3 days. The sporulated oo-
cysts were stored in 2% aqueous potassium dichromate solution at 11 °C
until used.
Each piglet was orally infected on SD 3 (for experimental setup, see
Table 1) with a single dose of approximately 1000 sporulated oocysts of
the respective C. suis strain using a flexible plastic Pasteur pipette.
Immediately after infection, piglets were either treated with BKI 1369
or mock treated with solvent (3% Tween 80 + 7% ethanol + 90%
0.9% NaCl) twice daily for five days from SD 3 to SD 7. Fine powder of
BKI 1369 was dissolved in the solvent to yield a 2.5% BKI solution,
which was used to treat individual piglets in groups Wien-BKI and Holl-
BKI twice daily at the rate of 10 mg/kg body weight (BW) (0.4 ml 2.5%
BKI 1369/kg BW). Furthermore, piglets infected with the Holland-I
isolate of C. suis (Holl-BKI and Holl-Ctrl) were additionally treated with
20mg/kg BW of toltrazuril (Baycox® 5%, Bayer Animal Health, Mon-
heim, Germany) to assure that only toltrazuril-resistant parasites were
present.
2.9. Post-treatment observations
Post-treatment observations were conducted by a veterinarian im-
mediately after the end of each treatment and 2 h post-treatment to
account for any adverse events associated with the treatment. All pig-
lets were examined post-treatment for systemic or regional responses
such as abnormal behavior, salivation/vomiting, ocular discharge, ab-
normal locomotion etc. In addition, all piglets were observed daily
during the course of the studies to ensure good general health and any
condition that required veterinary care was recorded and addressed.
2.10. Sample collection and efficacy parameters
The efficacy of BKI 1369 was evaluated by the assessment of oocyst
excretion, fecal consistency and body weight development. Individual
fecal samples were collected daily from SD 7 to SD 20 for the evaluation
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of fecal consistency and oocyst excretion. Fecal consistency was scored
immediately after sampling with fecal scores (FS) 1: normal/firm, FS 2:
pasty, FS 3: semi-liquid and FS 4: liquid, with FS 3 and FS 4 considered
as diarrhea. Fecal samples were screened for the presence of oocysts
qualitatively by autofluorescence (AF) followed by a quantitative
modified McMaster technique (Joachim et al., 2018b). Furthermore,
pooled fecal samples of each litter (SD 7) were examined for the pre-
sence of other entero-pathogens such as rotavirus, coronavirus, Es-
cherichia coli, and Clostridium perfringens. The body weight of each piglet
was recorded on SD 1, 8, 15, 22, 29 and additionally on the days of
treatment for calculation of the treatment doses.
Three piglets from group Wien-BKI and two piglets from group
Wien-Ctrl were sacrificed on SD 9 after the confirmed onset of oocyst
excretion in the mock treated group to collect jejunal tissue sections for
histopathology and transmission electron microscopy (TEM). In addi-
tion, jejunal mucosal scrapings were collected from each sacrificed
piglet. At the end of the experiment (SD 29), all remaining piglets from
groups Wien-BKI, Wien-Ctrl, Holl-BKI and Holl-Ctrl were sacrificed.
Blood samples with EDTA were collected from piglets in the group
Wien-BKI just before the first treatment, 2 h after the first treatment,
just before the 9th treatment, 2 h after the 9th treatment and at the end
of the study (SD 29). Plasma samples were obtained by centrifugation
(10min at 1500×g) and stored at −80 °C until use. All remaining
piglets in group Wien-BKI (n=10) were sacrificed at the end of the
study and urine samples were collected. To determine compound ex-
posure, BKI 1369 and its metabolites, BKI 1318 (metabolite 1) and BKI
1817 (metabolite 2) (Fig. 1) (Hulverson et al., 2017; Lee et al., 2018),
were extracted from the plasma and urine samples using acetonitrile/
0.1% formic acid with an internal standard. A standard curve was
prepared for comparison and quantification. The samples were ana-
lyzed by LC-MS/MS analysis on an ACQUITY ultra performance liquid
chromatography (UPLC) system in tandem with a Waters Xevo TQS
Micro (Waters Corporation, Milford, MA, USA).
2.11. Histopathology
At necropsy, jejunal mucosal scrapings and tissue sections were
collected from sacrificed piglets on SD 9. Jejunal sections for histo-
pathology were fixed in 10% neutral buffered formalin, embedded in
wax, processed, sectioned and stained with hematoxylin and eosin (H&
E) at the Institute of Pathology and Forensic Veterinary Medicine,
University of Veterinary Medicine Vienna, Austria. Air-dried mucosal
scrapings from the jejunum were fixed in methanol and stained with
Giemsa using standard procedures. Both H&E tissue sections and
Giemsa stained mucosal smears were examined for the presence of
developmental stages of C. suis at magnifications of 100× to 1000x.
2.12. Statistical analysis
Statistical calculations for in vivo trials were performed with RStudio
version 1.1.453 (RStudio Team, 2018), descriptive statistics with
Microsoft Excel 2010 (Microsoft Inc., Vienna, Austria) and GraphPad
Prism version 5.04 for Windows (GraphPad Software, San Diego,
California USA). Differences in clinical and parasitological parameters
between groups were analyzed with ANOVA in the case of normal
distribution and variance homogeneity of the data, or a Kruskal-Wallis
rank sum test if this was not the case. In the event of significance for the
omnibus tests parametric or non-parametric post-hoc tests for multiple
Table 1
Litters and treatment groups used in the trial; piglets were infected on study day 3 and treated with BKI 1369 from study day 3–7.
Group Infection with C. suis strain Litter No. No. of piglets in total No. of piglets that completed the studyc Treatment
Wien-BKI Wien-I 1, 2, 3 13 10 BKI; 10mg/kg BW, twice daily
Wien-Ctrl Wien-I 1, 2, 3 12 9 Mocka; twice daily
Holl-BKI Holland-I 4 5 5 BKI; 10mg/kgb BW, twice daily
Holl-Ctrl Holland-I 4 5 5 Mocka; twice daily§
a Mock: solvent (3% Tween 80 + 7% ethanol + 90% 0.9% NaCl).
b Piglets infected with Holland-I strain (Holl-BKI & Holl-Ctrl) were additionally treated with 20mg/kg BW toltrazuril.
c Three piglets from group Wien-BKI and two piglets from group Wien-Ctrl were sacrificed on SD 9 for collection of samples for histopathology. In addition, one
piglet from group Wien-Ctrl was found dead on SD 11. Only those piglets that completed the study were included in the analysis of efficacy.
Fig. 1. Chemical structure of bumped kinase inhibitor 1369 (BKI 1369) and its two major metabolites, BKI 1318 (metabolite 1) and BKI 1817 (metabolite 2).
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comparisons were performed (according to Tukey and Conover, re-
spectively), with P-value adjustment after Bonferroni. In vitro assays
were evaluated by t-tests in GraphPad Prism version 5.04 for Windows,
with significance reported at P < 0.05. For testing efficacy of BKI 1369
in vitro, the percentage of inhibition was calculated as follows:
= No of free merozoites counted in BKI treated culture at dpi
No of free merozoites counted in DMSO only treated culture at dpi
x
% inhibition




3.1. Expression of recombinant CsCDPK1
Comparative sequence analysis of the BKI-binding CDPKs in T.
gondii (TgCDPK1), N. caninum (NcCDPK1), S. neurona (SnCDPK1), H.
hammondi (HhCDPK1) and B. besnoiti (BbCDPK1) against the predicted
protein kinases of C. suis identified CSUI_000151 as the putative CDPK1
ortholog (Fig. 2). This CDPK1-type kinase in C. suis (CsCDPK1) showed
a high degree of sequence similarity in the ATP binding domain
with> 97% amino acid identity to the above mentioned apicomplexan
parasites including glycine as the gatekeeper residue.
CsCDPK1 was expressed in E. coli. Analysis of the recombinant ex-
pression by SDS-PAGE showed a protein band which matched the
predicted molecular weight of 60 kDa for the uncleaved, His-tagged
CsCDPK1 (Supplementary Fig. S1).
3.2. Functional assessment of CsCDPK1 in the presence of BKI 1369
Recombinant CsCDPK1 was characterized by thermal stability as-
says. Substantial shifts in melting temperature were observed in the
presence of BKI 1369 (9.7 °C and 8.0 °C in the presence of EGTA) re-
lative to 1817 (metabolite 2) (2.1 °C and 1.5 °C in the presence of EGTA)
and the no compound DMSO control (Supplementary Fig. S2A-C). Re-
combinant CsCDPK1 was found to have protein kinase activity by
transferring a phosphate group from ATP to PLKtide. The concentration
of BKIs required for 50% inhibition of CsCDPK1 enzyme activity (IC50)
was in the lower nanomolar range for BKI 1369 (4.5 nM), while BKI
1817, (metabolite 2), used as a negative control, had an IC50 value
of> 481 nM.
3.3. Viability of IPEC-1 cells in presence of BKI 1369
An in vitro assay was established to assess viability of IPEC-1 cells
upon exposure to BKI 1369. Incubation of uninfected cells with BKI
1369 at concentrations< 1 μM did not cause significant changes in cell
proliferation and viability (Supplementary Fig. S3) compared with that
of medium-only and DMSO-only controls (P > 0.05). Moreover, no
alterations in morphology of IPEC-1 cells were detected upon inspection
by light microscopy. Incubation of cells with 1 μM BKI 1369 for 4 days
significantly reduced the absorbance of WST-1, directly proportional to
cell viability, when compared to medium-only (P=0.0196) and
DMSO-only (P=0.0046) controls. Consequently, the highest
concentration of BKI 1369 used in subsequent culture assays was
200 nM.
3.4. Dose-response experiments
BKI 1369 inhibited the proliferation of C. suismerozoites cultured in
IPEC-1 cells with an IC50 of 40 nM, and parasite proliferation was al-
most completely inhibited (> 95%) at 200 nM. Incubation of host cells
immediately after infection up to 4 dpi resulted in a significant dose-
dependent reduction of free merozoite counts at 9 dpi for all tested
concentrations of BKI 1369 higher than 12.5 nM (P < 0.0001) (Fig. 3).
3.5. Light microscopy and TEM of in vitro samples
The effects of continued BKI 1369 treatment with IC50 and IC95
concentrations on C. suis propagated in IPEC-1 cells were visualized by
light microscopy. In BKI 1369 treated cultures, marked reductions in
the number of intracellular and free merozoites were observed
(Fig. 4A–C). Intracellular and free merogonic stages were frequently
observed in DMSO-only control cultures under a light microscope
compared to treated cultures. However, these concentrations had no
apparent effects on the ultrastructure of C. suis merozoites as analyzed
by TEM (Fig. 4D–F). Although fewer intracellular merozoites were
observed in longitudinal sections of treated cultures, they were con-
fined within a parasitophorous vacuole, surrounded by a para-
sitophorus vacuole membrane and exhibited typical features of all
apicomplexans including the apical complex with spirally arranged
conoid, micronemes, rhoptries and dense granules (Fig. 4D–F).
Fig. 2. Alignment of amino acid sequences of SnCDPK1, BbCDPK1, CsCDPK1, NcCDPK1, TgCDPK1 and HhCDPK1. The ATP binding region is shaded (grey);
Gatekeeper residue ‘glycine’ is marked in red. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this
article.)
Fig. 3. In vitro dose-dependent growth inhibition by BKI 1369; Cultures were
infected with Wien-I C. suis strain and treated immediately following infection
to 4 dpi.
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3.6. Oocyst excretion
Treatment with BKI 1369 completely suppressed oocyst excretion in
the group Wien-BKI and significantly limited excretion in group Holl-
BKI to a single positive sample on SD 8 (Fig. 5). In contrast, oocyst
shedding was observed in both mock treated control groups, Wien-Ctrl
and Holl-Ctrl, as early as SD 8, and by SD 12 all piglets in these groups
had excreted oocysts at least once. The mean duration of oocyst ex-
cretion was 5.3 ± 3.8 days in the group Wien-Ctrl and 2.8 ± 1.3 days
in the group Holl-Ctrl (Supplementary Table S1). All parameters related
to oocyst excretion such as the number of days with McMaster detect-
able oocyst excretion, the mean number of oocysts per grams of feces
(OpG) and the area under the curve (AUC) for OpG were significantly
different between the treated and control groups, irrespective of the C.
suis strain used (Table 2).
3.7. Fecal consistency and diarrhea
None of the piglets had diarrhea on the day of infection. The mean
daily FS in group Wien-BKI did not exceed 1.2 throughout the study and
was significantly lower than that of Wien-Ctrl (Fig. 6, Table 2). Three
samples in group Holl-BKI had a FS 3, but the FS in group Holl-BKI was
significantly lower than that of the Holl-Ctrl group throughout the
study (Table 2). The maximum prevalence of diarrhea was 100% in
group Holl-Ctrl (average duration 4.4 days) and 66.7% in group Wien-
Ctrl (average duration 2.4 days). Watery diarrhea (FS 4) was observed
in 33.3% and 100% of the piglets in groups Wien-Ctrl and Holl-Ctrl for
an average of 1.3 and 2.4 days, respectively.
3.8. Body weight
Body weights were not significantly different between the groups on
SD 1, the day of randomization (P=0.79). Daily weight gain and total
Fig. 4. Light microscopy and TEM analysis of BKI 1369 untreated and treated C. suis infected IPEC-1 monolayers 5 dpi; Compared to control culture (A) significantly
lower number of free merozoites counts were observed in cultures treated with IC50 (B) and IC95 (C) concentrations of BKI; Transmission electron micrograph of C.
suis merozoites in untreated (D) and BKI treated (E & F) cultures; con: conoid; rho: rhoptries; mic: microneme; dg: dense granule; nuc: nucleus; ld: lipid droplet; pvm:
parasitophorus vacuole membrane.
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weight gain from SD 1 to SD 29 were significantly higher in the group
Wien-BKI compared to Wien-Ctrl, whereas no such differences were
found between treated and control piglets infected with C. suis Holland-
I (Table 3). During the acute phase of infection (SD 15), mean body
weights were significantly higher in BKI-treated piglets compared to the
control groups, irrespective of the C. suis strains used (Fig. 7). Also, a
significant negative correlation between the mean fecal score and the
total weight gain was observed for all piglets (ρ=−0.518, P=0.02).
3.9. Differential diagnosis
Fecal samples pooled by litter on SD 7 were negative for rotavirus
and coronavirus whereas E. coli and Cl. perfringens could be detected in
all litters.
3.10. Safety
No piglets showed treatment-related adverse effects that required
veterinary intervention throughout the study period. Neither visible
signs of toxicity nor clinically relevant systemic or regional/local re-
sponses related to treatment were observed in the treated groups.
3.11. Histopathology of jejunal sections and mucosal scrapings
H&E stained sections of the mid-jejunum were examined for histo-
pathological changes characteristic of C. suis infections and for the
presence of developmental stages of the parasite. Compared to the
normal jejunal villi in BKI-treated piglets, mock treated control piglets
exhibited stunted villi atrophy and fusion (Fig. 8 A and C). Numerous
infected epithelial cells with distinct clustered merozoites of C. suis
were observed in stained jejunal sections of mock treated control piglets
(Fig. 8D). Giemsa-stained mucosal scraping smears from mock treated
piglets revealed the presence of matured crescent-shaped merozoites
within the parasitophorous vacuole (Fig. 9). Neither histopathological
alterations in the morphology of villi nor presence of endogenous stages
of C. suis could be detected in tissue sections and mucosal scraping
smears of BKI-treated piglets.
Fig. 5. Daily oocyst excretion ln (OPG+1) per group during the whole study
period as determined by McMaster technique.
Table 2
P values (given as –log10) for parameters of oocysts excretion and fecal score.







Area under the curve OpG 8.82 5.03 23.79; 3
Mean OpG 8.72 2.36 33.13; 3
Days with McMaster countable
oocysts excretion
8.56 4.23 23.40; 3
Mean fecal score 3.74 0.62 18.52; 3
Area under the curve FS 3.49 3.11 18.93; 3
Number of diarrhea days 3.72 2.99 20.00; 3
Fig. 6. Mean fecal scores of piglets throughout the sampling period of 14 days.
Table 3
Body weight development and body weight gains (in grams) with standard deviations in brackets. Differences at P < 0.05 are indicated in bold. SD: Study day.
Group SD 1 SD 8 SD 15 SD 22 SD 29 Total BWG
SD 1- SD 29
Daily weight gain
Wien-BKI 1898 [309.0] 3794 [550.9] 6102 [785.1] 8324 [995.8] 10896 [1298.0] 8998 [1158.1] 321.3 [41.3]
Wien-Ctrl 1762.2 [347.9] 3242.2 [670.3] 4755.5 [1042.1] 7042.2 [1405.6] 9446.6 [1678.6] 7684.4 [1410.4] 274.4 [50.3]
P 0.38 0.06 0.005 0.03 0.04 0.03 0.03
Holl-BKI 1868 [267.8] 3464 [517.7] 5480 [698.7] 7376 [968.4] 9492 [1145.9] 5536 [349.6] 272.2 [33.5]
Holl-Ctrl 1880 [223.1] 3200 [589.2] 3988 [783.2] 5976 [1295.6] 8204 [1652.4] 4649.6 [568.0] 225.8 [53.7]
P 0.94 0.47 0.01 0.08 0.1 0.1 0.1
Fig. 7. Body weight development in piglets after BKI 1369 treatment. Vertical
lines depict standard deviations.
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3.12. Pharmacokinetics
BKI 1369 and its metabolites BKI 1318 (metabolite 1) and BKI 1817
(metabolite 2) (Hulverson et al., 2017; Lee et al., 2018) were measured
in plasma and urine samples (Table 4). BKI 1369 concentrations of
4.9 μM were observed at 2 h after the 1st dose and rose to 11.7 μM 2 h
before the 9th dose, without further increase 2 h after the 9th dose
(10.2 μM). Metabolite levels remained low at all measured time points
and there was no compound detected in plasma or urine at 29 dpi.
4. Discussion
The role of CDPKs and their potential as molecular targets for
chemotherapeutic intervention in apicomplexan parasites has pre-
viously been studied in parasites of different taxonomic groups.
Apicomplexan CDPK1 regulates the calcium-dependent pathway of
microneme secretion, facilitates gliding locomotion and governs host
cell attachment, invasion and egress (Billker et al., 2009; Carruthers
and Sibley, 1999; Kieschnick et al., 2001; Wei et al., 2013). Contrary to
most mammalian kinases, the presence of glycine as a gatekeeper re-
sidue in the ATP-binding site of apicomplexan CDPK1 enables BKIs to
fit perfectly into a small hydrophobic pocket, rendering them highly
selective and promising compounds for therapeutic intervention against
these parasites.
Fig. 8. Histological sections of jejunum in C. suis infected 9-days-old piglets from group Wien-BKI (A–B) and Wien-Ctrl (C–D); Infection with C. suis resulted in stunted
and atrophied villi (C) with numerous asexual endogenous stage (arrows, D); (H&E stain).
Fig. 9. Giemsa stained mucosal scraping smears in C. suis infected piglets from group Wien-BKI (A) and Wien-Ctrl (B); Merozoites within parasitophorus vacuoles
could be observed in smears from group Wien-Ctrl (arrows, B).
Table 4
Concentrations of BKI 1369 and its metabolites, BKI 1318 (metabolite 1) and
BKI 1817 (metabolite 2) in piglets infected with Wien-I strain; dpi: days post-
infection.





BKI 1369 BKI 1318 BKI 1817
Plasma
2 dpi (0 h before 1st
dose)
6 0 ± 0 0 ± 0 0 ± 0
3 dpi (2 h after 1st dose) 6 4.9 ± 2.0 0.01 ± 0.01 0 ± 0
7 dpi (2 h before 9th
dose)
6 11.7 ± 4.8 0.2 ± 0.1 0.2 ± 0.01
7 dpi (2 h after 9th
dose)
6 10.2 ± 2.9 0.1 ± 0.1 0.02 ± 0.01
29 dpi (termination) 6 0 ± 0 0 ± 0 0 ± 0
Urine
29 dpi (termination) 5a 0 ± 0 0 ± 0 0 ± 0
a Urine sample of one piglet could not be obtained.
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The identified CDPK1-type kinase in C. suis, CsCDPK1, showed a
high degree of sequence similarity in the ATP binding domain with
TgCDPK1, HhCDPK1, BbCDPK1, SnCDPK1 and NcCDPK1 having> 97%
amino acid identity with glycine as the gatekeeper residue. Unlike all
the previously studied apicomplexan recombinant CDPK enzymes, the
peptide substrate syntide-2 (PLARTLSVAGLPGKK) was not compatible
for measurement of CsCDPK1 kinase activity in vitro. This is inspite of
the highly conserved amino acid sequence similarities between
CsCDPK1 and other CDPK1 enzyme active sites. However, CsCDPK1
auto-phosphorylation activity could be measured in the presence or
absence of calcium and with or without a suitable peptide substrate.
Experimental analysis confirmed its calcium dependency as determined
in phosphorylation reactions using EGTA as a Ca2+ chelator in the
presence or absence of PLKtide (Signalchem Richmond, BC, Canada)
peptide substrate (CKKLGEDQAEEISDDLLED-SLSDEDE). This calcium
dependent regulation of enzyme activity is a verification that it belongs
to the same family as previously described apicomplexan CDPKs (Van
Voorhis et al., 2017). Future studies will be needed to determine the
potential divergence of functions, natural substrates or pathways of
CsCDPK1 relative to other CDPKs. Nonetheless, sensitivity to BKIs by a
direct inhibition of enzyme activity was confirmed in direct enzyme
activity assay and further demonstrated indirectly by a thermal stabi-
lization assay.
The increase in the thermal melting temperature of recombinant
CsCDPK1 in the presence of BKI 1369 indicates binding of either ligand
to CsCDPK1, based on previous studies showing correlations between
binding affinities predicted by a thermal shift and direct measurement
of enzyme inhibition by compounds (Ojo et al., 2016). Additionally, the
IC50 concentration of BKI 1369 measured against recombinant
CsCDPK1 (4.5 nM) corroborated the efficacy of this compound in the in
vitro dose-response assay (IC50= 40 nM). Further validation of the re-
latedness of CsCDPK1 to TgCDPK1 was shown by improved EGTA
thermal stabilization of the enzymes relative to the control where Ca2+
is presumably bound to the recombinant enzyme (Supplementary Fig.
S2B) as previously reported (Scheele et al., 2018). This result seems
counterintuitive since calcium activates the enzymes, yet chelating
Ca2+ appears to maximize thermal stability (Scheele et al., 2018).
The in vitro IC50 and IC95 values obtained for BKI 1369 were in the
nanomolar range, which supports data published for efficacy against C.
parvum (Hulverson et al., 2017) and C. hominis (Lee et al., 2018).
Treatment of C. suis infected IPEC-1 cells with IC95 concentrations of
BKI 1369 for five days significantly reduced the number of free mer-
ozoites as seen in both light microscopy and TEM, without any apparent
effect in the ultrastructure of C. suis merozoites. In Toxoplasma and
Neospora treated with other BKIs such as BKI 1294, morphological al-
terations in vitro were only seen following longer treatment duration
with a very high dose of 2.5 μM (Ojo et al., 2014; Winzer et al., 2015).
However, this would not be an option in the in vitro model employed
here, since the host cells are sensitive to higher concentrations of BKI
1369 and, more significantly, C. suis has a time-limited developmental
phase terminating in oocyst production compared to the permanent
lytic cycle of tachyzoite replication in vitro in Toxoplasma and Neospora.
BKIs have been shown to inhibit host cell invasion, egress and cy-
tokinesis in vitro, as well as to reduce cerebral parasite burden in
standardized murine models of cyst-forming apicomplexan parasites
such as T. gondii and N. caninum (Doggett et al., 2014; Ojo et al., 2014;
Winzer et al., 2015). In a calf clinical model and an acute porcine model
of cryptosporidiosis, treatment with 10mg/kg BW BKI 1369 twice daily
for five days significantly reduced clinical diarrhea and fecal oocyst
excretion and improved overall health in infected animals (Lee et al.,
2018; Schaefer et al., 2016). The same treatment regime was adopted in
the present in vivo study to evaluate the therapeutic efficacy of BKI
1369, a candidate BKI with fewer known side effects compared to other
tested BKIs (Hulverson et al., 2017), against porcine cystoisosporosis in
its natural host.
The experimental model of suckling piglet cystoisosporosis was
previously employed to evaluate efficacy of anticoccidial treatment
based on quantitative and qualitative oocyst shedding, fecal con-
sistency/diarrhea, body weight development and general animal health
(Joachim and Mundt, 2011; Joachim et al., 2014, 2018b; Mundt et al.,
2006, 2007; Shrestha et al., 2015). In mammalian species an antic-
occidial is considered to be efficient in vivo when oocyst shedding is
noticeably reduced (indicating reduced environmental contamination
with parasite stages, i.e. reduced infection pressure) and animal health
and weight gain are improved compared to the mock-treated control
(Joachim et al., 2018a). Treatment with BKI 1369 significantly reduced
oocyst excretion and diarrhea in piglets infected with C. suis in the
presence of other entero-pathogens. The high efficacy of BKI 1369 in
reducing oocyst excretion and diarrhea is comparable to that of tol-
trazuril (Mundt et al., 2007; Joachim and Mundt, 2011; Joachim et al.,
2018b) and was observed irrespective of the parasite strain employed,
indicating that BKI 1369 therapy could be effective in combating tol-
trazuril susceptible as well as resistant C. suis.
It has been suggested that lesions induced by intracellular replica-
tion of C. suis impair physiological and functional balance of the in-
testine and therefore have a negative impact on body weight develop-
ment of piglets (Mundt et al., 2006). A similar effect of C. suis infection
was observed in this study with significantly lower daily body weight
gain and total weight gain in the control piglets compared to BKI 1369
treated piglets during the acute phase of infection. This effect tended to
wane in the following period (after SD 15), which might be due to
gradual healing of the intestinal epithelium and maturation of the im-
mune system with increasing piglet age, a general feature in coccidiosis.
Histological sections from mock treated control piglets revealed cu-
boidal villous epithelium, shortened villi and villous fusion together
with numerous merogonic stages of C. suis within parasitophorus va-
cuoles. In comparison, morphological alterations in the gut were not
observed in treated piglets, which underpins the hypothesis that C. suis-
induced intestinal damage disturbs the physiological function of the
intestine, ultimately leading to diarrhea, malabsorption of nutrients and
reduced weight gain (Lindsay et al., 1985; Stuart et al., 1982).
BKI 1369 achieved therapeutic concentrations in piglet plasma in
the micromolar range, far above the effective in vitro levels
(IC95= 200 nM). The plasma concentration already reached a peak 2 h
after the 1st dose and the concentration gradually increased to 11.7 μM
2 h before the 9th dose, indicating accumulation of the drug in plasma
after treatment twice daily for 5 days. Consequently, assuming similar
levels are found in infected gut epithelium, the in vivo parasites were
constantly exposed to very high concentrations of BKI 1369. This could
be the reason for the complete cessation of parasite development and
replication in vivo compared to in vitro experiments. These results are in
accordance with previous studies on BKI 1369 in C. hominis infected
piglets, which reported low concentrations of the metabolites during
the dosing period. Further pharmacokinetics studies in piglets to de-
termine the concentrations of BKI 1369 in gastrointestinal tissues over
time would be warranted to better understand the relationship between
efficacy and exposure at the infection sites. Also, since the plasma levels
reached the observed concentrations of 11.7 μM during dosing, well
above the 1 μM concentration that showed effects in vitro to IPEC-1 cell
viability, multi-dose toxicity studies that include blood chemistry and
histopathology would be warranted to fully assess any effects that BKI
1369 might have on the host species. In summary, the present study
evaluated therapeutic efficacy, pharmacokinetics and safety parameters
of BKI 1369 against porcine cystoisosporosis in an experimental infec-
tion of its natural host. Application of single drug concentration is one
of the major limitations of this study, due to which it was not possible to
determine minimal effective drug concentration and to develop prac-
tical drug application scheme. Oral applications of BKI 1369 were
highly effective in reducing oocyst shedding and diarrhea, and im-
proved body weight gain in piglets infected with C. suis, including the
toltrazuril-resistant Holland-I isolate, without adverse effects. The
successful outcome in both the in vitro culture and the animal infection
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model of porcine cystoisosporosis also strongly argues for developing
BKI 1369 as a chemotherapeutic compound against this disease, both in
pigs and in other mammals including humans (Shrestha et al., 2015).
However, BKI 1369 therapy in the field might have practicability issues,
owing to the need for multiple doses. Therefore, future studies on BKI
1369 should be concentrated towards ease of drug handling and re-
ducing treatment frequencies.
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